Matches in Nanopublications for { ?s ?p "Of relevance, lisdexamfetamine dimesylate, a psy- chostimulant approved for the treatment of ADHD, has been recently assessed and approved for the treat- ment of moderate to severe binge eating disorder in adults.5,6 In a phase 2 efficacy and safety trial, pa- tients with binge eating disorder who were prescribed doses of 50 and 70 mg/day doses of lisdexamfetamine demonstrated reduced binge eating days per week, greater binge eating cessation rates, and greater rates of clinical global improvement at 11 weeks compared with the placebo control group" ?g. }
Showing items 1 to 2 of
2
with 100 items per page.
- association label "Of relevance, lisdexamfetamine dimesylate, a psy- chostimulant approved for the treatment of ADHD, has been recently assessed and approved for the treat- ment of moderate to severe binge eating disorder in adults.5,6 In a phase 2 efficacy and safety trial, pa- tients with binge eating disorder who were prescribed doses of 50 and 70 mg/day doses of lisdexamfetamine demonstrated reduced binge eating days per week, greater binge eating cessation rates, and greater rates of clinical global improvement at 11 weeks compared with the placebo control group" assertion.
- association label "Of relevance, lisdexamfetamine dimesylate, a psy- chostimulant approved for the treatment of ADHD, has been recently assessed and approved for the treat- ment of moderate to severe binge eating disorder in adults.5,6 In a phase 2 efficacy and safety trial, pa- tients with binge eating disorder who were prescribed doses of 50 and 70 mg/day doses of lisdexamfetamine demonstrated reduced binge eating days per week, greater binge eating cessation rates, and greater rates of clinical global improvement at 11 weeks compared with the placebo control group" assertion.